Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects

Diabetologia

Volumn 49, Issue 12, 2006, Pages 3009-3016

  Goossens, G H ^a,b,c   Blaak, E E ^a,b,c   Schiffers, P M ^d   Saris, W H M ^a,b   Van Baak, M A ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Wageningen Centre for Food Sciences ^*  (Netherlands)

^c TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

ACE inhibition; Insulin sensitivity; Muscle blood flow; Skeletal muscle glucose uptake; Substrate oxidation

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; PLACEBO; RAMIPRIL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC OBESITY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FOREARM BLOOD FLOW; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN SYNTHESIS; LIPID OXIDATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; MIDDLE AGED; PLACEBOS; RAMIPRIL;

EID: 33750915439     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0458-2     Document Type: Article

References (41)

1. Cooper ME, Johnston CI (2000) Optimizing treatment of hypertension in patients with diabetes. JAMA 283:3177-3179
2. Sowers JR, Epstein M, Frohlich ED (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37:1053-1059
3. Jandeleit-Dahm KA, Tikellis C, Reid CM, Johnston CI, Cooper ME (2005) Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 23:463-473
4. Goossens GH, Blaak EE, Saris WH, Van Baak MA (2004) Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects. J Clin Endocrinol Metab 89:2690-2696
5. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME (2004) Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53:989-997
6. De Mattia G, Ferri C, Laurenti O, Cassone-Faldetta M, Piccoli A, Santucci A (1996) Circulating catecholamines and metabolic effects of captopril in NIDDM patients. Diabetes Care 19:226-230
7. Paolisso G, Balbi V, Gambardella A et al (1995) Lisinopril administration improves insulin action in aged patients with hypertension. J Hum Hypertens 9:541-546
8. Vuorinen-Markkola H, Yki-Jarvinen H (1995) Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 44:85-89
9. Falkner B, Canessa M, Anzalone D (1995) Effect of angiotensin converting enzyme inhibitor (lisinopril) on insulin sensitivity and sodium transport in mild hypertension. Am J Hypertens 8:454-460
10. Ferri C, Laurenti O, Bellini C et al (1995) Circulating endothelin-1 levels in lean non-insulin-dependent diabetic patients. Influence of ACE inhibition. Am J Hypertens 8:40-47
11. Pollare T, Lithell H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321:868-873
12. Henriksen EJ, Jacob S, Kinnick TR, Teachey MK, Krekler M (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38:884-890
13. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158-2169
14. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC (2002) Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 40:609-611
15. Santoro D, Natali A, Palombo C et al (1992) Effects of chronic angiotensin converting enzyme inhibition on glucose tolerance and insulin sensitivity in essential hypertension. Hypertension 20:181-191
16. Petrie JR, Morris AD, Ueda S et al (2000) Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 85:1882-1889
17. New JP, Bilous RW, Walker M (2000) Insulin sensitivity in hypertensive Type 2 diabetic patients after 1 and 19 days' treatment with trandolapril. Diabet Med 17:134-140
18. Wiggam MI, Hunter SJ, Atkinson AB et al (1998) Captopril does not improve insulin action in essential hypertension: a double-blind placebo-controlled study. J Hypertens 16:1651-1657
19. Ludvik B, Kueenburg E, Brunnbauer M, Schernthaner G, Prager R (1991) The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension. J Cardiovasc Pharmacol 18(Suppl 2):S157-S159
20. Valensi P, Derobert E, Genthon R, Riou JP (1996) Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp. Diabetes Metab 22:197-200
21. Pratt MC, Lewis-Barned NJ, Walker RJ (1993) A comparison between enalapril and captopril on insulin sensitivity in normotensive healthy volunteers. Aust NZ J Med 23:652-655
22. Heinemann L, Heise T, Ampudia J et al (1995) Four week administration of an ACE inhibitor and a cardioselective beta-blocker in healthy volunteers: no influence on insulin sensitivity. Eur J Clin Invest 25:595-600
23. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL (2000) Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342:905-912
24. Reaven GM, Clinkingbeard C, Jeppesen J et al (1995) Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure. Am J Hypertens 8:461-466
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
26. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol Endocrinol Metab 237:E214-E223
27. Blaak EE, Wagenmakers AJ, Glatz JF et al (2000) Plasma FFA utilization and fatty acid-binding protein content are diminished in type 2 diabetic muscle. Am J Physiol Endocrinol Metab 279:E146-E154
28. Weir JB (1949) New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 109:1-9
29. Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55:628-634
30. Ferrario CM, Brosnihan KB, Chappell M (1995) Measurements of angiotensin peptides. Hypertension 26:843-845
31. Frayn KN, Maycock PF (1980) Skeletal muscle triacylglycerol in the rat: methods for sampling and measurement, and studies of biological variability. J Lipid Res 21:139-144
32. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509
33. Laakso M, Edelman SV, Brechtel G, Baron AD (1990) Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance. J Clin Invest 85:1844-1852
34. Olsen MH, Fossum E, Hoieggen A et al (2005) Long-term treatment with losartan versus atenolol improves insulin sensitivity in hypertension: ICARUS, a LIFE substudy. J Hypertens 23:891-898
35. Hermann TS, Li W, Dominguez H et al (2006) Quinapril treatment increases insulin-stimulated endothelial function and adiponectin gene expression in patients with type 2 diabetes. J Clin Endocrinol Metab 91:1001-1008
36. Galletti F, Strazzullo P, Capaldo B et al (1999) Controlled study of the effect of angiotensin converting enzyme inhibition versus calcium-entry blockade on insulin sensitivity in overweight hypertensive patients: Trandolapril Italian Study (TRIS). J Hypertens 17:439-445
37. Goossens GH, Blaak EE, van Baak MA (2003) Possible involvement of the adipose tissue renin-angiotensin system in the pathophysiology of obesity and obesity-related disorders. Obes Rev 4:43-55
38. Janke J, Engeli S, Gorzelniak K, Luft FC, Sharma AM (2002) Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51:1699-1707
39. Okuno A, Tamemoto H, Tobe K et al (1998) Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361
40. Wendling PS, Peters SJ, Heigenhauser GJ, Spriet LL (1996) Variability of triacylglycerol content in human skeletal muscle biopsy samples. J Appl Physiol 81:1150-1155
41. Steffensen CH, Roepstorff C, Madsen M, Kiens B (2002) Myocellular triacylglycerol breakdown in females but not in males during exercise. Am J Physiol Endocrinol Metab 282:E634-E642